evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

240 questions · 247 findings · 23 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 35 · 14.2%GRADE not reported 13 · 5.3%Very low 50 · 20.2%Low 71 · 28.7%Moderate 65 · 26.3%High 13 · 5.3%

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in radiological changes: Erosion Scores (ES) Scale from: 0 to 230 compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher hypersensitivity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher pancreatitis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in osteonecrosis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher asparaginase‐associated toxicity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Overall survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in overall survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in event‐free survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Serum urate normalisation ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Total adverse events · participants with tophi in gout

Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Proportion with complete resolution of a target tophus · participants with tophi in gout

Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).

1 finding from 1 review

Monthly pegloticase vs placebo

Joint pain reduction ‐ not reported · participants with tophi in gout

The review found no eligible studies for this question.

1 finding from 1 review